An Alliance for Clinical Trials in Oncology study published in the Journal of Clinical Oncology reported high remission rates in older adults with B‑cell acute lymphoblastic leukemia using sequential inotuzumab ozogamicin followed by blinatumomab. Investigators documented unprecedented complete remission rates in a population historically difficult to treat with intensive chemotherapy. The regimen leverages antibody‑drug conjugate induction followed by a bispecific T‑cell engager consolidation, a chemo‑sparing approach that may reduce treatment‑related morbidity in older patients. Authors highlighted tolerability and rapid disease control as key advantages. If confirmed in broader practice and regulatory settings, the sequence could alter frontline management for older ALL patients, expand use of targeted immunotherapies and inform trial designs focused on reduced‑intensity regimens.